Oncology

Novogen granted patent for anticancer drug phenoxodiol

Published in Women's Health Weekly, December 25th, 2003

Pharmaceutical company Novogen (NASDAQ:NVGN), has been granted the U.S. patent covering methods for treating all benign and malignant cancers with the anticancer drug phenoxodiol, including ovarian cancer, breast cancer, prostate cancer and cervical cancer.

Phenoxodiol is currently in phase II human clinical trials in the U.S. and Australia, and the rights to commercialize phenoxodiol have been licensed to the Novogen majority-owned U.S. company Marshall Edwards, Inc.

Novogen Managing Director Christopher Naughton said the latest patent joined a suite of existing protection that consolidated and further secured Novogen's intellectual property...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2003-12-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry